Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma
After phase 2 trials showed promising survival for the combination of durvalumab during and after standard chemotherapy, collaborators in the US, Australia, and New Zealand open the phase 3 DREAM3R trial.